Tina Albertson
Net worth: 9 029 $ as of 2024-03-30
Profile
Tina Albertson worked as the Medical Director at Seagen Inc. from 2010 to 2015.
She then served as the Vice President-Global Drug Development at Juno Therapeutics, Inc. from 2015 to 2020.
Currently, she is the Chief Medical Officer & Head-Development at Lyell Immunopharma, Inc. since 2020.
Dr. Albertson holds a doctorate degree from Stanford University, the University of Washington, and an undergraduate degree from the University of Oregon.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0.00% | 2023-02-23 | 4,049 ( 0.00% ) | 9 029 $ | 2024-03-30 |
Former positions of Tina Albertson
| Companies | Position | End |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 2023-10-31 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 2020-03-31 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 2014-12-31 |
Training of Tina Albertson
| Stanford University | Doctorate Degree |
| University of Washington | Doctorate Degree |
| University of Oregon | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Tina Albertson
